OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
New frontiers in personalized medicine in psoriasis
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1431-1433
Closed Access | Times Cited: 55
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1431-1433
Closed Access | Times Cited: 55
Showing 1-25 of 55 citing articles:
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
Fabrizio Martora, Matteo Megna, Teresa Battista, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 135-148
Open Access | Times Cited: 50
Fabrizio Martora, Matteo Megna, Teresa Battista, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 135-148
Open Access | Times Cited: 50
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients
Matteo Megna, Elisa Camela, Teresa Battista, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 1, pp. 43-58
Closed Access | Times Cited: 44
Matteo Megna, Elisa Camela, Teresa Battista, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 1, pp. 43-58
Closed Access | Times Cited: 44
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients
Matteo Megna, Elisa Camela, Teresa Battista, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 1, pp. 25-41
Closed Access | Times Cited: 42
Matteo Megna, Elisa Camela, Teresa Battista, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 1, pp. 25-41
Closed Access | Times Cited: 42
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 6, pp. 537-552
Closed Access | Times Cited: 42
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 6, pp. 537-552
Closed Access | Times Cited: 42
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
Matteo Megna, Angelo Ruggiero, Teresa Battista, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3233-3233
Open Access | Times Cited: 30
Matteo Megna, Angelo Ruggiero, Teresa Battista, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3233-3233
Open Access | Times Cited: 30
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation
Angelo Ruggiero, Luca Potestio, Fabrizio Martora, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 5, pp. 355-362
Closed Access | Times Cited: 30
Angelo Ruggiero, Luca Potestio, Fabrizio Martora, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 5, pp. 355-362
Closed Access | Times Cited: 30
Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
Andrew Blauvelt, Andrea Chiricozzi, Benjamin D. Ehst, et al.
Advances in Therapy (2023) Vol. 40, Iss. 8, pp. 3410-3433
Open Access | Times Cited: 27
Andrew Blauvelt, Andrea Chiricozzi, Benjamin D. Ehst, et al.
Advances in Therapy (2023) Vol. 40, Iss. 8, pp. 3410-3433
Open Access | Times Cited: 27
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 829-842
Open Access | Times Cited: 9
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 829-842
Open Access | Times Cited: 9
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
Angelo Ruggiero, Fabrizio Martora, Gabriella Fabbrocini, et al.
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 2785-2793
Open Access | Times Cited: 36
Angelo Ruggiero, Fabrizio Martora, Gabriella Fabbrocini, et al.
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 2785-2793
Open Access | Times Cited: 36
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
Matteo Megna, Elisa Camela, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 1677-1690
Open Access | Times Cited: 20
Matteo Megna, Elisa Camela, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 1677-1690
Open Access | Times Cited: 20
Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?
Zuzana Jirásková Zákostelská, Zuzana Reiss, Helena Tlaskalová‐Hogenová, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 4, pp. 911-933
Open Access | Times Cited: 18
Zuzana Jirásková Zákostelská, Zuzana Reiss, Helena Tlaskalová‐Hogenová, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 4, pp. 911-933
Open Access | Times Cited: 18
Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments
Teresa Battista, Massimiliano Scalvenzi, Fabrizio Martora, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 1899-1932
Open Access | Times Cited: 16
Teresa Battista, Massimiliano Scalvenzi, Fabrizio Martora, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 1899-1932
Open Access | Times Cited: 16
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 841-852
Open Access | Times Cited: 6
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 841-852
Open Access | Times Cited: 6
JAK Inhibitors in Psoriatic Disease
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 3129-3145
Open Access | Times Cited: 15
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 3129-3145
Open Access | Times Cited: 15
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
Luca Potestio, Elisa Camela, Sara Cacciapuoti, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2045-2059
Open Access | Times Cited: 14
Luca Potestio, Elisa Camela, Sara Cacciapuoti, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2045-2059
Open Access | Times Cited: 14
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
Fabrizio Martora, Massimiliano Scalvenzi, Teresa Battista, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2525-2536
Open Access | Times Cited: 14
Fabrizio Martora, Massimiliano Scalvenzi, Teresa Battista, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2525-2536
Open Access | Times Cited: 14
Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study
Luca Potestio, Fabrizio Martora, Flavia Raia, et al.
Dermatology and Therapy (2025)
Open Access
Luca Potestio, Fabrizio Martora, Flavia Raia, et al.
Dermatology and Therapy (2025)
Open Access
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
Luca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Psoriasis Targets and Therapy (2023) Vol. Volume 13, pp. 19-26
Open Access | Times Cited: 11
Luca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Psoriasis Targets and Therapy (2023) Vol. Volume 13, pp. 19-26
Open Access | Times Cited: 11
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 51-57
Open Access | Times Cited: 4
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 51-57
Open Access | Times Cited: 4
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study
Matteo Megna, Angelo Ruggiero, Fabrizio Martora, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 9, pp. 2691-2691
Open Access | Times Cited: 4
Matteo Megna, Angelo Ruggiero, Fabrizio Martora, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 9, pp. 2691-2691
Open Access | Times Cited: 4
Digital health in psoriasis
Sarah N. Rimmer, Jessica N. Pixley, Steven R. Feldman
Elsevier eBooks (2025), pp. 387-416
Closed Access
Sarah N. Rimmer, Jessica N. Pixley, Steven R. Feldman
Elsevier eBooks (2025), pp. 387-416
Closed Access
Targeting Cytokine Dysregulation in Psoriasis: The Role of Dietary Interventions in Modulating the Immune Response
Daniel Simancas‐Racines, Náthaly Mercedes Román-Galeano, Ludovica Verde, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2895-2895
Open Access
Daniel Simancas‐Racines, Náthaly Mercedes Román-Galeano, Ludovica Verde, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2895-2895
Open Access
Foam-Based Drug Delivery Systems for Skin Disorders: A Comprehensive Review
Syrsulu Myrzagulova, Zhexenova Azhar N, Mohit Kumar, et al.
AAPS PharmSciTech (2025) Vol. 26, Iss. 4
Closed Access
Syrsulu Myrzagulova, Zhexenova Azhar N, Mohit Kumar, et al.
AAPS PharmSciTech (2025) Vol. 26, Iss. 4
Closed Access
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature
Fabrizio Martora, Teresa Battista, Claudio Marasca, et al.
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 2369-2382
Open Access | Times Cited: 17
Fabrizio Martora, Teresa Battista, Claudio Marasca, et al.
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 2369-2382
Open Access | Times Cited: 17
Rutaecarpine ameliorates imiquimod-induced psoriasis-like dermatitis in mice associated with alterations in the gut microbiota
Yongjian Li, Zhengping Tan, Wencan Li, et al.
Acta Biochimica et Biophysica Sinica (2024)
Open Access | Times Cited: 3
Yongjian Li, Zhengping Tan, Wencan Li, et al.
Acta Biochimica et Biophysica Sinica (2024)
Open Access | Times Cited: 3
